We hypothesized that in our early AD study group, PET Aβ would correlate with tau signal in areas affected early in the disease process and that change in cognitive impairment over 6 months would be most demonstrable in the subset of patients with greater Aβ and/or tau loading. This evidence concerns the gene MAPT and Cognitive impairment.